AI & Machine Learning
6d ago
Cellular Intelligence adds experts from AI and medicine to its advisory board to enhance drug development
Sep 21, 2026
AI Summary
Cellular Intelligence has appointed Robert Langer and Yann LeCun to its advisory board to advance its AI-driven approach to drug development, particularly for Parkinson's disease. The company aims to use AI to predict and control cell behavior, potentially speeding up the creation of new therapies.
- Cellular Intelligence is developing an AI model to predict and control cell behavior, aiming to streamline drug development processes.
- The company announced the addition of Robert Langer, Yann LeCun, Jens Nielsen, and Fabian Theis to its advisory board. Langer will also serve as a board observer.
- Langer is a co-founder of Moderna and a prominent medical researcher, while LeCun is a leading AI researcher known for his work in deep learning.
- The advisory board combines expertise in genomics, developmental biology, and AI to enhance the company's capabilities.
- Cellular Intelligence recently acquired global rights to STEM-PD, an experimental therapy for Parkinson's disease, which has received FDA Fast Track designation.
- The company plans to license its AI models for drug discovery and develop additional therapies in collaboration with pharmaceutical partners.
- Cellular Intelligence, founded in 2023 and previously known as Somite.ai, has raised over $70 million from various investors.
ai in medicineparkinsons drugbiotechcellular intelligenceyann lecun